文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

低剂量艾司洛尔通过调节T淋巴细胞凋亡与分化减轻脓毒症诱导的免疫抑制

LOW DOSE OF ESMOLOL ATTENUATES SEPSIS-INDUCED IMMUNOSUPPRESSION VIA MODULATING T-LYMPHOCYTE APOPTOSIS AND DIFFERENTIATION.
PubMed 文献 · Shock · 2023-02-28
一句话结论脓毒症大鼠模型中,低剂量艾司洛尔(5 mg·kg⁻¹·h⁻¹)减轻T淋巴细胞凋亡并恢复TH2/TH1比值,高剂量(18 mg·kg⁻¹·h⁻¹)无此效应。

研究在盲肠结扎穿刺(CLP)脓毒症休克大鼠模型中比较两种剂量艾司洛尔的作用:CLP后4小时随机分为CLP组、CLP+E-5组(艾司洛尔5 mg·kg⁻¹·h⁻¹)和CLP+E-18组(18 mg·kg⁻¹·h⁻¹),另设8只假手术大鼠;CLP后18小时评估血流动力学、器官组织损伤、外周血单个核细胞凋亡及T淋巴细胞亚群。结果:CLP+E-5组心率不变,低血压、乳酸血症和多器官损伤改善;T淋巴细胞凋亡和TH2/TH1比值降低;p-Akt、Bcl-2表达升高,cleaved Caspase-3和p-Erk1/2表达降低;两组β1-肾上腺素受体表达均无变化。CLP+E-18组心率下降,上述免疫与器官损伤指标未见改善。作者认为艾司洛尔可能通过Akt/Bcl-2/Caspase-3通路减轻T淋巴细胞凋亡、抑制Erk1/2活性减少TH0向TH2分化,可能成为脓毒症休克的潜在免疫调节剂。

要点

  • CLP脓毒症休克大鼠中,艾司洛尔5 mg·kg⁻¹·h⁻¹使心率不变,并改善低血压、乳酸血症和多器官损伤;18 mg·kg⁻¹·h⁻¹则使心率下降且上述指标未见改善。
  • 仅CLP+E-5组T淋巴细胞凋亡和TH2/TH1比值降低,CLP+E-18组未见降低。
  • CLP+E-5组脾CD4⁺T淋巴细胞p-Akt和Bcl-2表达升高,cleaved Caspase-3和p-Erk1/2表达降低。
  • CLP+E-5与CLP+E-18两组β1-肾上腺素受体表达均无变化。
  • 作者认为艾司洛尔可能通过Akt/Bcl-2/Caspase-3通路减轻T淋巴细胞凋亡、抑制Erk1/2活性减少TH0向TH2分化,可能是脓毒症休克的潜在免疫调节剂。

适用人群与场景

  • CLP脓毒症休克Wistar大鼠,CLP后4小时随机分组;另设8只假手术大鼠。
  • 动物实验,非临床人群。

处置流程与药物剂量

  • CLP后4小时给予艾司洛尔5 mg·kg⁻¹·h⁻¹(CLP+E-5组)或18 mg·kg⁻¹·h⁻¹(CLP+E-18组)。
  • CLP后18小时评估血流动力学、器官组织损伤、外周血单个核细胞凋亡、T淋巴细胞亚群及脾CD4⁺T淋巴细胞蛋白表达。

研究设计与关键结果

  • CLP诱导心动过速、低血压、高乳酸血症和多器官损伤。
  • 心率在CLP+E-5组不变,在CLP+E-18组下降。
  • 低血压、乳酸血症和多器官损伤仅在CLP+E-5组改善。
  • T淋巴细胞凋亡和TH2/TH1比值在CLP+E-5组降低,CLP+E-18组未降低。
  • CLP+E-5组p-Akt和Bcl-2表达升高,cleaved Caspase-3和p-Erk1/2表达降低。
  • β1-肾上腺素受体表达在CLP+E-5和CLP+E-18两组均无变化。

证据类型、等级与局限

  • 动物实验(Wistar大鼠CLP脓毒症休克模型)。
  • 作者认为艾司洛尔可能通过Akt/Bcl-2/Caspase-3通路减轻T淋巴细胞凋亡、抑制Erk1/2活性减少TH0向TH2分化;艾司洛尔可能是脓毒症休克的潜在免疫调节剂。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 原文为动物实验,作者认为低剂量艾司洛尔可能调节脓毒症休克免疫抑制,高剂量可能因心率下降而不改善器官损伤指标。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Background: Immunosuppression caused by immune cell apoptosis and an imbalance of T helper 2 cells (T H 2) and T helper 1 cells (T H 1), is associated with poor outcomes in septic patients. Esmolol was reported to improve survival by modulating immune responses in septic shock. Whether esmolol could alleviate sepsis-induced immunosuppression and the optimal dose are unclear. Methods: Four hours after cecal ligation and puncture (CLP), Wistar rats were randomized into CLP, CLP + E-5 (esmolol: 5 mg·kg -1 ·h -1 ) and CLP + E-18 (esmolol: 18 mg·kg -1 ·h -1 ) groups. Eight rats were underwent sham operation. Eighteen hours after CLP, hemodynamics and organ histological injuries were evaluated, peripheral blood mononuclear cells apoptosis and T-lymphocyte subsets counts were determined by flow cytometry, and the expression of p-Akt, Bcl-2, cleaved Caspase-3, and p-Erk1/2 in splenic CD4 + T-lymphocytes was determined by western blot and immunohistochemistry. β 1 -Adrenoreceptor expressions were evaluated using real-time polymerase chain reaction and immunohistochemistry. Results: Cecal ligation and puncture induced tachycardia, hypotension, hyperlactatemia, and multiple organ injury. Heart rate was unchanged in the CLP + E-5 group but decreased in the CLP + E-18 group. Hypotension, lactatemia, and multiple organ injuries were improved only in the CLP + E-5 group. T-lymphocyte apoptosis and T H 2/T H 1 ratio was decreased in CLP + E-5 but not in CLP + E-18. p-Akt and Bcl-2 expressions were increased, while cleaved Caspase-3 and p-Erk1/2 expressions were decreased in CLP + E-5. β 1 -Adrenoreceptor expressions were unchanged in both CLP + E-5 and CLP + E-18 groups. Conclusions: Low dose of esmolol reduced T-lymphocyte apoptosis and restored T H 2/T H 1 ratio in septic shock. Esmolol might modulate Akt/Bcl-2/Caspase-3 pathway to relieve T-lymphocyte apoptosis and inhibit Erk1/2 activity to decrease T H 0 differentiation to T H 2. Esmolol may be a potential immunoregulator of septic shock.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Ma Y, Cheng Z, Zheng Y, et al. LOW DOSE OF ESMOLOL ATTENUATES SEPSIS-INDUCED IMMUNOSUPPRESSION VIA MODULATING T-LYMPHOCYTE APOPTOSIS AND DIFFERENTIATION. Shock. 2023. PMID: 36852973. doi:10.1097/SHK.0000000000002104

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。